Angion is a biopharmaceutical company discovering and developing novel therapeutic agents for acute and chronic organ injuries, with an initial focus on nephrology. Angion’s therapeutic programs modulate the natural protective, reparative and regenerative pathways of the body in both orphan diseases and larger clinical indications. The Company’s preclinical and clinical portfolio targets areas of high unmet need across a spectrum of therapeutic indications, including acute kidney injury (AKI), chronic kidney disease (CKD) and chronic fibrosis. For more information, please visit www.angion.com.